Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Antibacterial Activity and Toxicity Profiles of Eclipta prostrata (L.) L. Extracts and Conventional Antibiotics against Bacterial Triggers of Some Autoimmune Diseases

    Web AdminBy Web AdminMay 5, 2023Updated:May 5, 2023No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Tianchen Cai1, Ian E. Cock1, 2,*

    1School of Environment and Science, Griffith University, Nathan, Queensland, AUSTRALIA.

    2Centre for Planetary Health and Food Security, Nathan Campus, Griffith University, Nathan, Queensland, AUSTRALIA.

    DOI: 10.5530/pc.2023.2.11

    ABSTRACT

    Background: Eclipta prostrata (L.) L. has been used traditionally to treat numerous diseases, including many caused by bacterial pathogens. However, E. prostrata extracts are yet to be tested for the ability to inhibit the growth of bacterial triggers of autoimmune diseases. Materials and Methods: Antimicrobial activity was assessed using disc diffusion and liquid dilution minimum inhibitory concentration (MIC) assays against a panel of bacterial triggers of some autoimmune diseases. Interactions between the E. prostrata extracts and conventional antibiotics were studied and classified using the sum of the fractional inhibitory concentration (ΣFIC). The toxicity of the individual samples and the combinations was assessed using the Artemia lethality assay (ALA). Results: Eclipta prostrata leaf extracts displayed notable antibacterial activity against the bacterial triggers of rheumatoid arthritis (P. mirabilis and P. vulgaris), ankylosing spondylitis (K. pneumoniae), and multiple sclerosis (A. baylyi and P. aeruginosa). The aqueous extract was a particularly good inhibitor of Proteus spp. growth. (MICs = 165μg/mL), whilst lower potency was noted against other bacterial pathogens. Furthermore, combining the extracts with conventional antibiotics resulted in potentiation of the inhibitory activity for some combinations, particularly those containing chloramphenicol as the antibiotic component. None of the individual components (nor the combinations) were toxic in the ALA assay. Conclusion: The E. prostrata methanolic, aqueous and ethyl acetate extracts displayed clinically relevant antibacterial activity against P. mirabilis and P. vulgaris, and lower potency against K. pneumonia, A. baylyi and P. aeruginosa when tested alone. The lack of toxicity of the extract and combinations indicates that E. prostrata extract and antibiotic combinations may provide leads in the development of new therapies to prevent and treat the autoimmune diseases rheumatoid arthritis, ankylosing spondylitis and multiple sclerosis.

    Keywords: Bringaraja, Medicinal plants, Rheumatoid arthritis, Ankylosing spondylitis, Multiple sclerosis, Conventional antimicrobials, Synergy, Drug interaction.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up